BRAF and non-small cell lung carcinoma: Indeed, FDA has approved the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to be administrated concurrently for treatment of patients with metastatic NSCLC harboring BRAF V600E mutation, as well as the KRAS inhibitor sotorasib for treatment of NSCLC patients harboring KRAS-G12C mutation.